The Drive to Discover. The Experience to Deliver.
JAK = Janus-associated kinase; IDO1 = indoleamine 2,3-dioxygenase; PI3K= phosphatidylinositol 3-kinase; FGFR = fibroblast growth factor receptor; BRD = Bromodomain
a. Incyte licensed rights outside the United States to Novartis and retained US rights.
b. Several clinical trials in patients with myelofibrosis are ongoing, including long-term extension studies, alternative dosing studies, joint global trials with Novartis and trials in patients with low platelet counts.
c. Trial not yet initiated.
d. In combination with Merck’s pembrolizumab.
e. In combination with Genentech’s MPDL3280A.
f. In combination with AstraZeneca/MedImmune’s MEDI4736.
g. In combination with Bristol-Myers Squibb’s nivolumab.
h. Incyte licensed worldwide rights to Novartis and retained codevelopment and copromotion options.
i. Incyte licensed worldwide rights to Eli Lilly and Company and elected to codevelop with Lilly and retained a copromotion option.
j. Incyte licensed worldwide rights to Lilly and retained a copromotion option.
k. Incyte licensed worldwide rights to Lilly and retained codevelopment and copromotion options.